Guidelines for treating various conditions can be helpful in setting practice standards, but the presence of several sets of guidelines from different countries, experts, and settings, written at different times, can also create confusion. Here we provide a ''guideline of guidelines'' for the treatment of schizophrenia, or ''meta-guidelines,'' which not only reconcile the various existing standards but also update them to include the use of several newer agents, most of which were marketed following the publication of existing standards.
Introduction
Managing patients with schizophrenia can be challenging, even for the most experienced of clinicians. Over the past decade, numerous experts in various countries have made recommendations in a number of published guidelines. [1] [2] [3] [4] [5] [6] [7] [8] In addition, many institutions and hospitals have their own unpublished versions of guidelines for how to treat patients with schizophrenia. Often these recommendations contradict one another and are quickly out of date as the ever-increasing influx of new data accumulate and novel therapeutic agents are made available. In the ''meta-guidelines'' presented here, we have collected recommendations from various sources, both published and unpublished, and have updated and reconciled the differences from the Patient Outcomes Research Team (PORT), the Texas Medication Algorithm Project (TMAP), the American Psychiatric Association (APA), various state and federal hospitals, and current experts with decades of experience in treating this patient population in order to create an up-to-date ''guideline of guidelines.'' These meta-guidelines have also been extensively reviewed by a number of anonymous peer reviewers. The goal was to create a comprehensive yet concise set of meta-guidelines that reflects all the current data in order to provide clinicians with an aid in the management of patients with schizophrenia at different stages of illness, including acute and maintenance phases. Although clinical judgment must be exercised in the care of individual patients, these meta-guidelines may serve to assist clinicians in choosing the most evidencebased and up-to-date strategies for addressing treatment selection, medication-induced side effects, treatment nonadherence, and other issues commonly encountered in treating patients with schizophrenia. These metaguidelines are intended for rank-and-file patients with schizophrenia who are not violent, self-harming, or complicated by various comorbidities, as such patients are excluded from most evidence-based randomized controlled efficacy trials that are the basis of both previously published guidelines and also of the metaguidelines provided here. [1] [2] [3] [4] [5] [6] [7] [8] We will provide separate meta-guidelines for more complex, yet commonly encountered patients with schizophrenia, for use and guidance for what to do when the meta-guidelines provided here fail to provide adequate outcomes. [9] [10] [11] [12] [13] [14] The meta-guidelines are presented here as Tables 1-15 and Figure 1 . Re-evaluation of serum drug levels, especially in cases where optimal drug efficacy is not obtained or medications known to alter levels are added > Recommendations for acute-phase treatment J Rapid emergency treatments for acutely psychotic patients showing aggressive behaviors: å Short-acting parenteral antipsychotic with or without parenteral benzodiazepine and with or without a parenteral anticholinergic å Rapidly dissolving oral formulations or oral concentrates of atypical antipsychotics J Use atypical antipsychotics as first-line treatment å Atypical antipsychotics may have superior efficacy for treating cognitive, negative, and affective symptoms å Use lower doses in first-episode individuals because they are more sensitive to extrapyramidal side effects (EPS) and metabolic side effects å For some patients, conventional antipsychotics may be first choice Note: Conventional antipsychotics may be as effective as atypical antipsychotics for acute phase treatment.
J Clozapine should be used in patients with persistent suicidality, violence, or substance abuse Note: Clozapine tends to be underutilized in some treatment settings, or utilized later than recommended (ie, following multiple antipsychotic treatment failures rather than just two or three) J Clozapine augmentation with an atypical or a conventional agent or electroconvulsive therapy (ECT) should be preceded by a treatment-refractory evaluation including: å Clozapine serum levels å Re-examining diagnosis å Substance abuse å Treatment adherence å Psychosocial stressors Note: Clozapine may also be superior for treatment-resistant symptoms. Tables 11 and 12 ) å Higher dosing for multi-episode patients å Maintenance doses lower than acute treatment doses å Lower doses in elderly and children J Adequate treatment trial å Wait a minimum of 3 weeks and maximum of 6 weeks before making a major change to the treatment regimen å In patients showing a partial response, extend trial duration to 4-10 weeks [5] [6] [7] [8] See full prescribing information for details. [5] [6] [7] [8] See full prescribing information for details. **Chlorpromazine equivalents represent the approximate dose equivalent to 100 mg of chlorpromazine (relative potency). [5] [6] [7] [8] See full prescribing information for details. Figure 1 . Antipsychotic algorithm for schizophrenia. For many acute inpatient settings with limited lengths of stay, trials of antipsychotics may be only 2-3 weeks prior to trying another. Many clinicians do not proceed to clozapine at all or until multiple failures with other antipsychotics; clozapine can be underutilized when this is the case. Response is generally defined as a clinically significant reduction in symptoms, eg, a modest 20% reduction in Positive and Negative Symptom Scale (PANSS) score observed at 2 weeks can predict a more robust 40% decrease in PANSS at 6 months. Lack of any response at 2 weeks is discouraging and requires reevaluation, including compliance and pharmacokinetics/therapeutic drug levels.
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